B-Raf signalling comprises the activation of the proto-oncogene product B-Raf and its downstream effectors and represents a key regulatory step in the activation of the canonical MAP kinase pathway by various extracellular stimuli and oncogene products such as RAS and activated receptor tyrosine kinases like NTRK and RET. Aberrant B-Raf activity as a result of somatic mutations is observed in 8 % of human cancers.
|Publisher Name||Encyclopedia of Cancer|
|URL link to publisher's version||http://www.springer.com/biomed/cancer/book/978-3-540-36847-2|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/10168|